Synthesis and Evaluation of Novel Compounds with Anticancer Activity
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2555
Special Issue Editors
Interests: chemotherapy; anti-cancer drugs; vitamin B6 (pyridoxine); derivatives of curcumin and dehydrozingerone; preclinical drug study
2. JSC "Tatchempharmpreparaty", Kazan, Russia
Interests: preclinical and clinical drug study; anticancer drugs; analogs of estradiol; ABC transporters; multidrug resistance
Special Issue Information
Dear Colleagues,
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Drug treatment, together with surgical operation, radiotherapy and biotherapy, constitute the main approaches to cancer treatment. Small molecules—products of chemical synthesis—are still the basis of classical anticancer drugs, such as alkylating agents, antimetabolites, antibiotics, vinca alkaloids, taxanes and topoisomerase inhibitors. Classical anticancer drugs target general biological processes such as DNA synthesis and mitosis and, therefore, are characterized by low selectivity and high cytotoxicity towards rapidly dividing normal cells. Despite this, small molecules still make up 75% of the anticancer drug market, and are cheaper to manufacture, and easier to pack into tablets and capsules for oral use than biological macromolecules. Additionally, small molecules can provide targeted tumor therapy, in particular tyrosine kinase inhibitors, such as imatinib, which block the proliferation of tumor cells that overexpress tyrosine kinases. In this regard, the synthesis and evaluation of small antitumor molecules remains an urgent task for researchers to this day. A newer direction is the synthesis of therapeutic peptides, polypeptides and nucleic acids, which are also of great interest for the development of anticancer drugs. Contributors are encouraged to submit manuscripts and reviews covering but not limited to the following topics:
- Synthesis of novel analogs of known anticancer agents and evaluation of their biological activity;
- Synthesis and evaluation of natural alkaloid derivatives (such as curcumin, dehydrozingerone, colchicine, vinca alkaloids and others) with anticancer activity;
- Synthesis and evaluation of short peptides and polypeptides that can inhibit tumour cell proliferation or migration, or suppress the formation of tumour blood vessels;
- Development and evaluation of siRNAs, shRNAs and other types of nucleic acids as an effective approach to silence cancer-causing genes.
Dr. Oksana Viktorovna Bondar
Dr. Alfiya Iksanova
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer agents
- synthesis
- design
- biological activity
- natural products
- anticancer peptides
- anticancer nucleic acids
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
